Cite
HARVARD Citation
Krug, L. et al. (n.d.). Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet oncology. 16 (4), pp. 447-456. [Online].